Phase 2 N=40 Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Hypogonadism
Primary: Percent of Subjects With Testosterone Levels in the Normal Range. — 68.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty
Elastosis
Primary: Acute Thermal Injury Depth — 195; 763 micrometers — p=<0.001
N/A N=32 Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin
Healthy
Primary: Visual Inspection of Baseplate Loosening — 3.77; 4.88 cm^2
Phase 2 N=13 Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
Hyperoxaluria
Primary: Urinary Oxalate Excretion — 1.43; 1.04 umol/mg — p=0.007
Phase 2 N=31 The Effects of Thalidomide on Symptom Clusters
Advanced Cancers
Primary: Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS) — 3; 3; 4; 3 units on a scale
Phase 2 N=8 Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage — 57.25; 39.40; 27.25; 25.45 percentage of BSA involvement
Phase 3 N=55 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms · Ascites
Primary: Time to Repeat Paracentesis (TRP) — 23.3; 55.1 days — p=0.0019
N/A N=162 Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
Arthritis, Rheumatoid
Primary: Incidence of Lymphoproliferative Disorders (LPD) — NA; NA; NA; NA LPD per 100 person-years
Phase 3 N=151 Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Pulmonary Hypertension
Primary: Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance — 8.4; 18.2; 17.7; 20.2 walk distance change from baseline (m)
Phase 2 N=239 Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
Multiple Sclerosis
Primary: Overview of Adverse Events [AE] — 35; 35; 33; 39 participants
N/A N=199 Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
Depression
Primary: Hamilton Rating Scale for Depression (HAM-D) — -6.7; -7.5; -5.7 units on a scale — p=<0.05
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
Phase 2 N=139 A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Number of Participants With Clinical Response 70 at Week 4 — 14; 13; 18; 16 participants
Phase 3 N=691 A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26. — -1.43; -1.12 percentage of total hemoglobin — p=<.001
Phase 2 N=260 Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
Binge Eating Disorder
Primary: Change From Baseline in Log Transformed Binge Days Per Week at Week 11 — -1.23; -1.24; -1.49; -1.57 Log days — p=0.8825